ArticleScientific reports2025
Decoding potential lncRNA and disease associations through graph representation learning and gradient boosting with histogram.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical value and regulatory role of lncRNA HOXB-AS3 in gastric cancer.World journal of surgical oncology · 2026Article
- CELLetter: leveraging large language model and dual-stream network to identify context-specific ligand-receptor interactions for cell-cell communication analysis.Briefings in bioinformatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Long noncoding RNAs (lncRNAs) are important regulators and promising targets for complex diseases. They have manifested dense relationships with various diseases. Although laboratory techniques have validated many lncRNA-disease associations (LDAs), they are costly, laborious, and time-consuming. This study introduces LDA-GMCB, an LDA inference model, by leveraging graph embedding learning, multi-head self-attention mechanism (MSA) with convolutional neural network (CNN), low-rank singular value decomposition (SVD), and histogram-based gradient boosting (HGBoost). For all lncRNAs and diseases, LDA-GMCB first deciphers their nonlinear features by incorporating graph embedding learning and MSA with CNN, then captures their linear features through low-rank SVD, and finally infers their relationships based on HGBoost. LDA-GMCB was compared with four baselines (i.e., SDLDA, LDNFSGB, IPCARF and LDA-VGHB) under 5-fold cross validation and two cold start scenarios, and four popular classifiers (i.e., multi-layer perceptron, SVM, random forest, and XGBoost). Additionally, LDA-GMCB implemented ablation study. The outcomes demonstrated that LDA-GMCB greatly surpassed the above models and gained significant improvement on two public databases (i.e., lncRNADisease and MNDR) under most conditions. Moreover, LDA-GMCB was further applied to infer potential lncRNAs for Alzheimer's disease and Parkinson's disease. It identified that DGCR5 and HIF1A could link with the two diseases, respectively. We hope that LDA-GMCB help infer potential lncRNAs for various complex diseases. LDA-GMCB is freely available at https://github.com/smiling199/LDA-GMCB .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.